R&D expense revenue share of Fosun Pharmaceutical 2019-2022
In 2022, the Chinese pharmaceutical firm Fosun Pharmaceutical invested approximately 13 percent of its revenue in research and development, up from about 12.8 percent in the previous year. In that year, the total research and development expenditure was almost six billion yuan.